SCHEMBL6300260

SCHEMBL6300260

COc1cc(Cl)ccc1Cn1c(C)nc2nc(Br)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.39
P2RX3 P56373 1/20 0.36
S1PR4 O95977 2/20 0.36
KMT2A Q03164 1/20 0.36
DCTPP1 Q9H773 2/20 0.36
GALR3 O60755 1/20 0.34
NR2F2 P24468 1/20 0.34
RAB9A P51151 1/20 0.34
HPGD P15428 2/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ABL1 P00519 1/20 0.34
POLB P06746 1/20 0.34
RIN1 Q13671 1/20 0.34
SLC6A2 P23975 2/20 0.34
SLC6A4 P31645 2/20 0.34
SLC6A3 Q01959 1/20 0.34
CCR2 P41597 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6300306 0.85 KMT2A (0.39) S1PR4KMT2AGALR3NR2F2RAB9A
SCHEMBL6299738 0.85 KMT2A (0.39) PDE2AS1PR4KMT2ADCTPP1GALR3
SCHEMBL6299201 0.81 HDAC3 (0.38) PDE2AP2RX3KMT2ADCTPP1GALR3
SCHEMBL6300044 0.74 PPARG (0.36) KMT2ADCTPP1GALR3NR2F2RAB9A
SCHEMBL6301746 0.70 PPARG (0.45) S1PR4DCTPP1RAB9AHPGDALDH1A1
SCHEMBL6300871 0.70 MRGPRX4 (0.47) S1PR4KMT2ADCTPP1HPGDMAPT
SCHEMBL28995797 0.69 KDM4E (0.45) KMT2AGALR3NR2F2RAB9AHPGD
SCHEMBL4854789 0.69 KCNH2 (0.48) PDE2AKDM4C
SCHEMBL20762014 0.68 NPSR1 (0.49) KMT2AMAPTHTTAKT1NPSR1
SCHEMBL6300511 0.68 NPSR1 (0.41) KMT2AHPGDALDH1A1HTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911469-B2 Sulfonamide compounds and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-28 US disclosed
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-09-16 US disclosed
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-07-25 US disclosed
US-6348474-B1 COMPOUNDS AS ANTIDIABETIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-02-19 US disclosed
EP-0995742-A1 SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity PDE2A, PDE3A, PDE12 PDE2A 1/4885P2RX3 614/4885S1PR4 448/4885
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications PDE2A, PDE3A, PYGM PDE2A 1/4885P2RX3 1144/4885S1PR4 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.